-
-
-
-
-
-
-
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
-
-
-
-
-
-
-
Banco Santander Chile: First Quarter 2026 Analyst and Investor Webcast / Conference Call
-
-
-
-
-
-
-
Banco Santander-Chile Announces Fourth Quarter 2025 Earnings
-
-
-
-
-
-
-
Banco Santander Chile: Third Quarter 2025 Analyst and Investor Webcast / Conference Call
-
-
-
-
-
-
-
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
-
-
-
-
-
-
-
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
-
-
-
-
-
-
-
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
-
1,206,275 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

